Biotechnology

Friday Aug 30, 2024 - 2:15 pm

InvestorNewsBreaks – Annovis Bio Inc. (NYSE: ANVS) Expands Team in Continued Focus to Make Meaningful Impact on Lives of AD, PD Patients

Annovis Bio (NYSE: ANVS), a pioneering late-stage clinical drug platform company focusing on transformative therapies for neurodegenerative disorders such as Alzheimer’s Disease (“AD”) and Parkinson’s Disease (“PD”), recently welcomed four seasoned professionals to its executive team. “Annovis Bio is excited about the new additions and confident that these highly experienced professionals will significantly contribute to the company’s mission of developing transformative therapies for neurodegenerative diseases.…

Thursday Aug 29, 2024 - 9:26 am

InvestorNewsBreaks – Safety Shot (NASDAQ: SHOT) Partners with Digital eCommerce Experts to Grow Online Presence

Safety Shot (NASDAQ: SHOT), a wellness company, is partnering with VENDO, a fully customizable, multipurpose eCommerce platform. Safety Shot has created the world's first alcohol detoxifier that reduces blood alcohol content by supporting its metabolism in as little as 30 minutes. According to the announcement, VENDO is an Amazon expert and Walmart marketplace wizard that works directly with brands to drive strategic and sustainable growth…

Monday Aug 26, 2024 - 9:43 am

InvestorNewsBreaks – Evofem Biosciences Inc. (EVFM) Subsidiary Appoints Industry Veteran as Subsidiary President

Aditxt (NASDAQ: ADTX), an innovation platform dedicated to discovering, developing and deploying promising health innovations, has announced a new president for its majority-owned subsidiary, Pearsanta Inc. According to the announcement, Christoper Mitton has been named president of the subsidiary, which focuses on precision health. Mitton has an impressive career of leadership in the medical diagnostics space spanning more than two decades. His experience includes building and…

Thursday Aug 22, 2024 - 2:30 pm

InvestorNewsBreaks – PaxMedica Inc. (PXMD) Committed to Global Health, Potential Positive Impact of PAX-101

PaxMedica (OTC: PXMD), a biopharmaceutical company specializing in neurological disorder treatments, is preparing to submit a New Drug Application (“NDA”) to the U.S. Food and Drug Administration for suramin to treat Human African Trypanosomiasis (“HAT”). “In April 2024, PaxMedica underscored its commitment to global health by responding to an urgent request from Malawi for an emergency release of suramin, demonstrating its dedication to advancing healthcare…

Thursday Aug 22, 2024 - 11:51 am

InvestorNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) CEO Featured in Upcoming Virtual Investor CEO Connect Segment

CNS Pharmaceuticals (NASDAQ: CNSP), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system, will be spotlighted in this month’s Virtual Investor CEO Connect. According to the announcement CNS Pharmaceuticals CEO John Climaco will participate in a live moderated webcast to begin at 12 p.m. ET on Aug. 26, 2024. During the webcast,…

Wednesday Aug 21, 2024 - 1:29 pm

InvestorNewsBreaks – Aditxt Inc. (NASDAQ: ADTX), Appili Therapeutics (TSX: APLI) (OTC: APLIF) Enter Third Amending Agreement

Aditxt (NASDAQ: ADTX), an innovation platform dedicated to discovering, developing and deploying promising health innovations, has entered into a third amending agreement with Appili Therapeutics Inc. (TSX: APLI) (OTC: APLIF), a biopharmaceutical company focused on developing innovative treatments and vaccines to combat some of the most challenging infectious diseases and potential bioterrorism threats. According to the agreement, Aditxt, through its wholly owned subsidiary Adivir Inc., will…

Wednesday Aug 21, 2024 - 9:28 am

InvestorNewsBreaks – GeoVax Labs Inc. (NASDAQ: GOVX) Enters $8.5M Registered Direct Offering with Institutional Investor

GeoVax Labs (Nasdaq: GOVX), a clinical-stage biotechnology company developing immunotherapies and vaccines against cancer and infectious diseases, has entered into a definitive securities purchase agreement with a certain institutional investor. The agreement is for the purchase and sale of 1,700,000 shares of the company’s common stock (or common stock equivalents), offered at $5 per share as part of a registered direct offering. The company will…

Monday Aug 19, 2024 - 2:02 pm

InvestorNewsBreaks – Processa Pharmaceuticals Inc. (NASDAQ: PCSA) Announces Positive Data from Two Preclinical Studies of NGC-Iri

Processa Pharmaceuticals (NASDAQ: PCSA), a clinical-stage pharmaceutical company focused on developing the next generation of chemotherapeutic drugs with improved efficacy and safety, today announced positive data from two preclinical studies. The data support the potential for the Next Generation irinotecan (“NGC-Iri”), the prodrug of SN-38, which is the active anticancer metabolite of irinotecan, to have improved efficacy and a better side effect profile compared with…

Monday Aug 19, 2024 - 9:29 am

InvestorNewsBreaks – Oragenics Inc. (NYSE American: OGEN) Reports on Status of Lead Drug Candidate Designed to Treat Concussion

Oragenics (NYSE American: OGEN), a company focused on developing unique, intranasal pharmaceuticals for the treatment of neurological disorders, has released a business status update. According to the update, which outlines key 2024 progress, the company continues to move forward on developing and advancing its lead candidate, ONP-002, for the treatment of concussion. Specifically, the update noted that phase 2 human trials are slated to begin…

Friday Aug 16, 2024 - 3:03 pm

InvestorNewsBreaks – InMed Pharmaceuticals Inc.’s (NASDAQ: INM) INM-089 Showing Great Promise in Treating AMD

InMed Pharmaceuticals (NASDAQ: INM), a clinical stage company developing a pipeline of pharmaceutical drug candidates to treat several diseases with a high unmet medical need, is at the forefront of developing innovative treatment for age-related macular degeneration (“AMD”), with its flagship product INM-089 showing great promise. “AMD is a prevalent eye condition that primarily affects older adults, leading to vision loss in the central part…

Thursday Aug 15, 2024 - 10:13 am

InvestorNewsBreaks — HeartBeam Inc. (NASDAQ: BEAT) Releases Q2 2024 Financial Report, Operational Update

HeartBeam (NASDAQ: BEAT), a medical technology company focused on transforming cardiac care through the power of personalized insights, is reporting on financial and operations results for its second quarter 2024, the period that ended June 30, 2024. Highlights of the report include steady progress made toward key clinical and regulatory milestones on its HeartBeam AIMIGo(TM) System, including the 510(k) submission to the U.S. Food and…

Thursday Aug 15, 2024 - 9:34 am

InvestorNewsBreaks — Annovis Bio Inc. (NYSE: ANVS) Announces Q2 2024 Financial Results, Provides Update Showing ‘Productive’ Recent Months

Annovis Bio (NYSE: ANVS), a late-stage, drug-platform company developing novel therapies for neurodegenerative diseases such as Alzheimer’s (“AD”) and Parkinson’s disease (“PD”), today released financial results for its second quarter ended June 30, 2024, and provided a business update. According to the update, results from the company’s completed Phase 2/3 AD study showed that buntanetap significantly improved cognition in patients with early AD. Additionally, data from…

Wednesday Aug 14, 2024 - 1:28 pm

InvestorNewsBreaks — Annovis Bio Inc. (NYSE: ANVS) Given $21.00 Price Target by EF Hutton

Annovis Bio (NYSE: ANVS), a late-stage, drug-platform company developing novel therapies for neurodegenerative diseases such as Alzheimer’s (“AD”) and Parkinson’s disease (“PD”), recently had its price target set at $21.00. The price target was issued by Jason Kolbert from EF Hutton on August 13, 2024. At the time of the announcement, Annovis Bio was trading at $7.87. “The overall price target consensus is at $26.00 with…

Wednesday Aug 14, 2024 - 10:41 am

InvestorNewsBreaks — NextPlat Corp. (NASDAQ: NXPL), Progressive Care (RXMD) Release Q2 2024 Financial Results Showing 474% Revenue Increase

NextPlat (NASDAQ: NXPL), a global e-Commerce provider, has released record financial results for its second fiscal quarter, the period ended June 30, 2024; the results include the consolidation of the operations of its e-commerce business with the results of its healthcare operations, Progressive Care Inc. (OTCQB: RXMD). Highlights of the report indicate the company experienced a 474% increase in consolidated Q2 revenues, which totaled $17 million, and a…

Wednesday Aug 14, 2024 - 9:57 am

InvestorNewsBreaks – Evofem Biosciences Inc. (EVFM) Releases Second-Quarter 2024 Financial Results, Company Update

Evofem Biosciences (OTCQB: EVFM) is reporting on its financial results and corporate update for Q2 2024; the report also included a report on the first half of 2024. Aditxt (NASDAQ: ADTX), a company dedicated to discovering, developing and deploying promising health innovations, entered into a merger agreement with Evofem last year; the agreement was amended and restated in July 2024, with a targeted close for later…

Wednesday Aug 14, 2024 - 9:20 am

InvestorNewsBreaks — Vistagen Therapeutics Inc. (NASDAQ: VTGN) Releases Q1 2025 Financial, Corporate Report

Vistagen Therapeutics (NASDAQ: VTGN), a late clinical-stage, neuroscience-focused biopharmaceutical company dedicated to the development and commercialization of groundbreaking therapies for psychiatric and neurological disorders based on nose-to-brain neurocircuitry, is reporting its financial results for the first quarter 2025, or the period ended June 30, 2024. The report also included a status update on the company’s pipeline, including fasedienol for the acute treatment of social anxiety…

Wednesday Aug 14, 2024 - 9:00 am

InvestorNewsBreaks – Oragenics Inc. (NYSE American: OGEN) Reports Concussion Drug Stable Across Wide Range of Temps

Oragenics (NYSE American: OGEN), a company focused on developing unique, intranasal pharmaceuticals for the treatment of neurological disorders, recently completed the synthesis of its ONP-002 drug batch for its upcoming planned phase 2 clinical trial. Consequently, the company is reporting that ONP-002, its lead candidate for treating concussion, is stable across a wide temperature range, thus eliminating the need for cumbersome cold storage during transport…

Tuesday Aug 13, 2024 - 12:37 pm

InvestorNewsBreaks – Aditxt Inc. (NASDAQ: ADTX) Releases Report on Annual Shareholders’ Meeting Activity

Aditxt (NASDAQ: ADTX), an innovation platform dedicated to discovering, developing and deploying promising innovations, is reporting on the results of its recent annual shareholders' meeting. According to the announcement, all nine proposed agenda items were successfully passed. Those proposals include the election of directors, the ratification of auditors, and the issuing of shares for Series B-1 and B-2 convertible preferred stock.In addition, a proposed Equity Line…

Tuesday Aug 13, 2024 - 11:12 am

InvestorNewsBreaks – Predictive Oncology Inc. (NASDAQ: POAI) Announces Expansion of Live-Cell Tumor Platform Applications

Predictive Oncology (NASDAQ: POAI), a leader in artificial-intelligence (“AI”)-driven drug discovery and biologics, has expanded the available applications for its platform to account for patient heterogeneity, derisk drug discovery and accelerated pipeline development. The company announced that its findings demonstrate real-world applications of POI’s AI platform to support biomarker discovery, clinical trial optimization and target validation; the platform also offers a proprietary tool that accounts…

Friday Aug 09, 2024 - 11:36 am

InvestorNewsBreaks – Aditxt Inc. (NASDAQ: ADTX) Enters into $1.2M Registered Direct Offering Agreement

Aditxt (NASDAQ: ADTX), an innovation company developing and commercializing technologies with a focus on monitoring and modulating the immune system, has entered into a securities purchase agreement with certain institutional investors. The agreement outlines a registered direct offering for the purchase and sale of 1,130,189 shares of common stock or common stock equivalents for $1.06 per share. Proceeds from the offering are projected to total approximately…

Friday Aug 09, 2024 - 10:26 am

InvestorNewsBreaks — IGC Pharma Inc. (NYSE American: IGC) Releases Q1 2025 Financial, Operational Results Report

IGC Pharma (NYSE American: IGC), a clinical-stage pharmaceutical company, is reporting on the results for its first fiscal quarter of 2025, the period ended on June 30, 2024. According to the report, highlights for the company included the company’s collaboration with Pablo Arbelaez, a renowned AI expert and researcher, in the development of the phase 2 clinical trial of IGC-AD1, the lead therapeutic candidate addressing agitation…

Thursday Aug 08, 2024 - 1:17 pm

InvestorNewsBreaks – Clene Inc. (NASDAQ: CLNN) CEO Spotlighted in Recent BioMedWire Podcast Episode

Clene (NASDAQ: CLNN), a late clinical-stage biopharmaceutical company focused on improving mitochondrial health and protecting neuronal function to treat neurodegenerative diseases, was featured in the latest episode of the BioMedWire Podcast, which is part of a sustained effort by IBN (Investor Brand Network) to provide specialized content distribution via widespread syndication channels. During the episode, Clene CEO and president Rob Etherington talks with IBN’s Carmel…

Thursday Aug 08, 2024 - 12:34 pm

InvestorNewsBreaks – Cybin Inc. (NYSE American: CYBN) (Cboe CA: CYBN) Releases Q1 2025 Financial Results, Business Highlights

Cybin (NYSE American: CYBN) (Cboe CA: CYBN), a clinical-stage biopharmaceutical company developing new and innovative next-generation psychedelic-based treatment options, today reported unaudited financial results for its first quarter of fiscal 2025 ended June 30, 2024 (“Q1 2025”) and provided recent business highlights. In the report, the company noted continued progress towards initiating its Phase 3 multinational study for the CYB003 program in late summer of…

Thursday Aug 08, 2024 - 11:44 am

InvestorNewsBreaks — Annovis Bio Inc. (NYSE: ANVS) Reports on ‘Synergistic Effect’ of Lead Compound Plus GLP-1 in AD Treatment Model

Annovis Bio (NYSE: ANVS), a late-stage, clinical-drug platform company pioneering transformative therapies for neurodegenerative disorders such as Alzheimer’s disease (“AD”) and Parkinson’s disease (“PD”), is reporting new preclinical data regarding buntanetap, its lead compound. According to the report, the date demonstrates the synergistic effect of buntanetap when combined with the glucagon-like peptide 1 (“GLP-1”) agonist dulaglutide (Trulicity[R]) in a mouse model of Alzheimer’s disease. The announcement…

Thursday Aug 08, 2024 - 9:15 am

InvestorNewsBreaks – Oragenics Inc. (NYSE American: OGEN) Reports Concussion Drug Passes FDA-Required Cardiotoxicity Testing

Oragenics (NYSE American: OGEN), a company focused on developing unique, intranasal pharmaceuticals for the treatment of neurological disorders, is reporting that ONP-002, its lead candidate for treating concussion, has successfully completed a study indicating the substance does not cause cardiotoxicity. Testing pharmaceuticals on cardiac receptors to ensure that they do not show any causes of electrical malformations is required by the U.S. Food and Drug…

Wednesday Aug 07, 2024 - 2:50 pm

InvestorNewsBreaks – Scorpius Holdings Inc. (NYSE American: SCPX) Releases Public Offering Pricing for Public Offering

Scorpius Holdings (NYSE American: SCPX), an integrated contract-development and manufacturing organization (CDMO), has announced the pricing of an underwritten public offering. The offering is comprised of 12,500,000 shares of common stock or prefunded warrants. Each share of common stock or prefunded warrant is offered at $1. According to the announcement, the company has estimated gross proceeds of approximately $12,500,000, before underwriting discounts and offering expenses…

Wednesday Aug 07, 2024 - 9:54 am

InvestorNewsBreaks – Clene Inc. (NASDAQ: CLNN) Releases Q2 2024 Financial Results, Provides Updates

Clene (NASDAQ: CLNN) (along with its subsidiaries, “Clene”) and its wholly owned subsidiary Clene Nanomedicine Inc., a clinical-stage biopharmaceutical company focused on improving mitochondrial health and protecting neuronal function to treat neurodegenerative diseases, including amyotrophic lateral sclerosis (“ALS”) and multiple sclerosis (“MS”), today released its Q2 2024 financial results. In addition, the company provided recent updates on its CNM-Au8(R) programs evaluating the use of CNM-Au8…

Wednesday Aug 07, 2024 - 9:42 am

InvestorNewsBreaks — Annovis Bio Inc. (NYSE: ANVS) Release Promising Clinical Data As Global Alzheimer’s Disease Therapeutics Market Grows

Annovis Bio (NYSE: ANVS), a late-stage, clinical-drug platform company pioneering transformative therapies for neurodegenerative disorders such as Alzheimer’s disease (“AD”) and Parkinson’s disease (“PD”), has released preclinical data from a study of its lead compound, buntanetap. According to the announcement, the study showed the synergistic effect of buntanetap combined with the glucagon-like peptide 1 (GLP-1) agonist dulaglutide (Trulicity[R]) in enhancing cognition in a mouse model of…

Tuesday Aug 06, 2024 - 12:33 pm

InvestorNewsBreaks — Astiva Health Announces Launch of Investor Relations Website to Facilitate Transparent, Effective Communication

Astiva Health, a leader in innovative and culturally aware healthcare solutions, today announced the launch of its new Investor Relations website. The launch marks a significant step and milestone in the company’s journey towards becoming a public company. It emphasizes Astiva Health’s commitment to maintaining transparent and effective communication and building strong relationships with investors, stakeholders, and the broader financial community. The platform will offer…

Tuesday Aug 06, 2024 - 11:22 am

InvestorNewsBreaks – Clene Inc. (NASDAQ: CLNN) Submits New CNM-Au8 Biomarker, Clinical Efficacy Data to FDA

Clene (NASDAQ: CLNN), a late-stage biopharmaceutical company focused on protecting mitochondrial health and neuronal function to treat neurodegenerative diseases, and its wholly owned subsidiary Clene Nanomedicine Inc., have submitted new data to the U.S. Food and Drug Administration (“FDA”). The data is regarding CNM-Au8(R) biomarker and clinical efficacy information, including post hoc analyses from two phase 2 clinical trials of CNM-Au8 for the treatment of ALS; the…

Tuesday Aug 06, 2024 - 9:37 am

InvestorNewsBreaks — Longeveron Inc. (NASDAQ: LGVN) Schedules Release of Q2 2024 Financial Results, Earnings Conference Call

Longeveron (NASDAQ: LGVN), a clinical-stage, regenerative-medicine biotechnology company developing cellular therapies for rare, life-threatening and chronic aging-related conditions, is planning to release its second-quarter 2024 financial report after markets close on Aug. 14, 2024. The company also announced that it has scheduled a conference call and webcast on the same day to discuss the report and provide a company update; the call will begin at…

Monday Aug 05, 2024 - 3:08 pm

InvestorNewsBreaks — PaxMedica Inc. (NASDAQ: PXMD) Preparing for NDA Submission for Leading Drug Candidate

PaxMedica (OTC: PXMD), a biopharmaceutical company focused on advancing treatments for neurological disorders, is in the process of preparing to submit a New Drug Application (“NDA”) to the U.S. Food and Drug Administration (“FDA”). The NDA is for PAX-101, an intravenous formulation of suramin that could potentially treat conditions such as Human African Trypanosomiasis and autism spectrum disorder (“ASD”). The process includes having a Type…

Monday Aug 05, 2024 - 10:56 am

InvestorNewsBreaks – TRxADE Health Inc.’s (NASDAQ: MEDS) Subsidiary Expands Capabilities with Changes to Executive Leadership Team

TRxADE Health (NASDAQ: MEDS), a pharmaceutical exchange platform provider, and its wholly owned subsidiary Scienture, LLC, a New York based branded specialty pharmaceutical company, today announced changes to Scienture’s executive leadership team. According to the announcement, Narasimhan Mani, Ph.D., MBA, an experienced healthcare professional and a proven health leader with over 25 years of experience in the pharmaceutical industry, has been appointed Scienture’s President. Additionally,…

Monday Aug 05, 2024 - 9:40 am

InvestorNewsBreaks — Annovis Bio Inc. (NYSE: ANVS) CEO Featured in Latest Bell2Bell Podcast, Recorded Live at AAIC 2024

Annovis Bio (NYSE: ANVS), a late-stage, clinical-drug platform company pioneering transformative therapies for neurodegenerative disorders such as Alzheimer’s disease (“AD”) and Parkinson’s disease (“PD”), is spotlighted in the latest episode of The Bell2Bell Podcast, released by IBN, a multifaceted communications organization engaged in connecting public companies to the investment community. The episode, which featured Annovis Bio founder, president and CEO Dr. Maria Maccecchini, PhD, was recorded…

Monday Aug 05, 2024 - 9:28 am

InvestorNewsBreaks – Clene Inc. (NASDAQ: CLNN) Announces Participation in Upcoming Canaccord Genuity 44th Annual Growth Conference & Private Company Showcase

Clene (NASDAQ: CLNN) (along with its subsidiaries, “Clene”) and its wholly owned subsidiary Clene Nanomedicine Inc. is a clinical-stage biopharmaceutical company focused on improving mitochondrial health and protecting neuronal function to treat neurodegenerative diseases, including amyotrophic lateral sclerosis (“ALS”) and multiple sclerosis (“MS”). The company is set to present at the Canaccord Genuity 44th Annual Growth Conference & Private Company Showcase and host 1x1 investor…

Friday Aug 02, 2024 - 10:40 am

InvestorNewsBreaks — Better Choice Company (NYSE American: BTTR) Closes on $5M Public Offering

Better Choice Company (NYSE American: BTTR), a pet health and wellness company, has closed on its public offering. The offering consisted of 639,000 shares of common stock as well as prefunded warrants to purchase 1,028,000 shares of its common stock. According to the announcement, each share of common stock and prefunded warrant was sold at $3 per share (inclusive of the prefunded warrant exercise price),…

Friday Aug 02, 2024 - 9:47 am

InvestorNewsBreaks – CEL-SCI Corp. (NYSE American: CVM) Closes on $10.8M Best-Efforts Offering

CEL-SCI (NYSE American: CVM), a cancer immunotherapy company, recently announced the closing of its previously announced best-efforts offering. The transaction involved the sale of 10,845,000 shares of the company’s common stock (or pre-funded warrants in lieu thereof) at an offering price of $1.00 per unit (inclusive of the pre-funded warrant exercise price). The offering raised $10,845,000 in gross proceeds before deductions. CEL-SCI intends to use…

Monday Jul 29, 2024 - 9:09 am

InvestorNewsBreaks — Longeveron Inc. (NASDAQ: LGVN) Lomecel-B(TM) Study Results Presented at the Alzheimer’s Association International Conference

Longeveron (NASDAQ: LGVN), a clinical-stage, regenerative-medicine biotechnology company developing cellular therapies for rare, life-threatening and chronic aging-related conditions, is presenting results from its Clear Mind phase 2a clinical trial at the Alzheimer’s Association International Conference(R) (“AAIC”). The conference began on July 28, 2024, and runs through Aug. 1, 2024; the event is being held in person in Philadelphia as well as online. According to the announcement,…

Friday Jul 26, 2024 - 12:47 pm

InvestorNewsBreaks – Silo Pharma Inc. (NASDAQ: SILO) to Participate in Upcoming H.C. Wainwright Annual Global Investment Conference

Silo Pharma (NASDAQ: SILO), a developmental-stage biopharmaceutical company focused on developing novel formulations and drug-delivery systems for traditional therapeutics and psychedelic treatments, will be presenting at the H.C. Wainwright 25th Annual Global Investment Conference. The conference is scheduled for Sept. 9–11, 2024, and will be held both virtually and in person in New York City. According to the announcement, virtual participation will be staged simultaneously with…

Friday Jul 26, 2024 - 11:57 am

InvestorNewsBreaks – TRxAde Health Inc. (NASDAQ: MEDS), Scienture Inc. Announce All-Stock Business Combination Resulting in Combined Company

TRxADE Health (NASDAQ: MEDS), a parent company of pharmaceutical business-to-business (“B2B”) exchange platform, has entered into a business combination with Scienture Inc. in an all-stock transaction. Scienture is a New-York-based pharmaceutical company that develops unique specialty product concepts and solutions. According to the announcement, TRxADE acquired all of Scienture’s assets in exchange for a combination of TRxADE common stock and nonvoting convertible preferred stock. In addition,…

InvestorNewsBreaks

NewsBreak Category: Biotechnology

Get Started with InvestorWire

Press Distribution

Explore Press Distribution Solutions

Discover Add-on Solutions